Effects of THC/CBD oromucosal spray on spasticity-related symptoms in people with multiple sclerosis: results from a retrospective multicenter study
- 25 April 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Neurological Sciences
- Vol. 41 (10), 2905-2913
- https://doi.org/10.1007/s10072-020-04413-6
Abstract
Introduction The approval of 9-δ-tetrahydocannabinol (THC)+cannabidiol (CBD) oromucosal spray (Sativex®) in Italy as an add-on medication for the management of moderate to severe spasticity in multiple sclerosis (MS) has provided a new opportunity for MS patients with drug-resistant spasticity. We aimed to investigate the improvement of MS spasticity-related symptoms in a large cohort of patients with moderate to severe spasticity in daily clinical practice. Materials and methods MS patients with drug-resistant spasticity were recruited from 30 Italian MS centers. All patients were eligible for THC:CBD treatment according to the approved label: ≥ 18 years of age, at least moderate spasticity (MS spasticity numerical rating scale [NRS] score ≥ 4) and not responding to the common antispastic drugs. Patients were evaluated at baseline (T0) and after 4 weeks of treatment (T1) with the spasticity NRS scale and were also asked about meaningful improvements in 6 key spasticity-related symptoms. Results Out of 1615 enrolled patients, 1432 reached the end of the first month trial period (T1). Of these, 1010 patients (70.5%) reached a ≥ 20% NRS score reduction compared with baseline (initial responders; IR). We found that 627 (43.8% of 1432) patients showed an improvement in at least one spasticity-related symptom (SRSr group), 543 (86.6%) of them belonging to the IR group and 84 (13.4%) to the spasticity NRS non-responders group. Conclusion Our study confirmed that the therapeutic benefit of cannabinoids may extend beyond spasticity, improving spasticity-related symptoms even in non-NRS responder patients.Keywords
This publication has 36 references indexed in Scilit:
- Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticityJournal of Neurology, Neurosurgery & Psychiatry, 2016
- MObility ImproVEment with spasticity in multiple sclerosis in Europe: the MOVE 1 EU studyNeurodegenerative Disease Management, 2014
- Spasticity in patients with multiple sclerosis - clinical characteristics, treatment and quality of lifeActa Neurologica Scandinavica, 2013
- Natural History of Multiple Sclerosis SymptomsInternational Journal of MS Care, 2013
- Correlation between spasticity and quality of life in patients with multiple sclerosis: the CANDLE studyInternational Journal of Neuroscience, 2013
- Costs and quality of life in multiple sclerosis patients with spasticityActa Neurologica Scandinavica, 2013
- Spasticity in multiple sclerosis: results of a patient surveyInternational Journal of Neuroscience, 2013
- Clinical efficacy and effectiveness of Sativex®, a combined cannabinoid medicine, in multiple sclerosis-related spasticityExpert Review of Neurotherapeutics, 2012
- Épidémiologie et évaluation clinique de la spasticité dans la sclérose en plaquesRevue Neurologique, 2012
- Managing neuropathic pain with Sativex®: a review of its pros and consExpert Opinion on Pharmacotherapy, 2008